수액용 풍선 카테터 시장 예측(2026-2032년)

The Infusion Balloon Catheter Market is projected to grow by USD 2,084.73 million at a CAGR of 12.23% by 2032.

Infusion Balloon Catheters: Executive Summary

Infusion balloon catheters combine balloon dilation with localized delivery of fluids, medications, or other therapeutic agents during minimally invasive procedures. Their clinical relevance is linked to the need for controlled treatment delivery, vessel access, procedural efficiency, and reduced reliance on more invasive interventions. Adoption is shaped by clinical evidence, device safety, operator training, reimbursement, hospital investment, and regulatory requirements.

Clinical Integration Is Reshaping Infusion Balloon Catheter Use

The landscape is shifting toward catheter platforms that support more precise lesion crossing, predictable balloon inflation, controlled infusion, and compatibility with image-guided workflows. Hospitals and physicians increasingly assess devices through a combination of procedural outcomes, ease of use, deliverability, visibility, and post-procedure safety rather than through a single technical feature. These changes favor designs that fit established treatment pathways while reducing workflow complexity.

Artificial Intelligence Is Strengthening Planning, Guidance, and Quality Control

Artificial intelligence is contributing to the broader interventional ecosystem through image interpretation, anatomical segmentation, lesion characterization, procedural planning, navigation assistance, and retrospective quality review. For infusion balloon catheter procedures, AI may help clinicians identify treatment targets, select procedural approaches, and monitor consistency when integrated with imaging and clinical information systems. The practical impact remains dependent on validated datasets, interoperability, cybersecurity, clinician oversight, and evidence that algorithmic support improves safety or efficiency without adding workflow burden.

Regional Insights: Uneven Access but Broad Procedural Relevance

North America is characterized by advanced interventional infrastructure, specialist expertise, and structured evaluation of device safety and outcomes. Europe combines mature clinical systems with detailed regulatory and health-technology requirements, while Asia-Pacific includes rapidly expanding procedural capacity alongside substantial variation in reimbursement and hospital resources. Latin America is influenced by unequal access, import dependence, and concentration of specialist care in major urban centers. The Middle East is investing in tertiary and specialty-care capabilities, particularly in leading urban systems, while Africa continues to face constraints involving equipment availability, referral pathways, training, and maintenance support. Across all regions, local regulatory alignment, physician education, and dependable supply chains are central to adoption.

Group Insights: Policy Alignment and Health-System Capacity Matter

ASEAN presents diverse regulatory systems and healthcare capabilities, making local registration, distributor competence, and clinician training important. BRICS economies combine large and varied patient populations with differing procurement structures, domestic manufacturing policies, and access conditions. The European Union emphasizes harmonized regulatory processes, clinical evidence, and cross-border quality expectations. G7 health systems generally have sophisticated clinical infrastructure but apply rigorous scrutiny to safety, reimbursement, and value. GCC countries are strengthening advanced hospital services and often prioritize high-quality imported technologies, while NATO members span highly developed and resource-constrained systems, making procurement resilience, interoperability, and emergency-care readiness relevant considerations.

Country Insights: Regulation, Infrastructure, and Specialist Expertise Define Adoption

Australia benefits from established specialist care and evidence-oriented procurement. Brazil and Mexico face regional disparities and procurement complexity alongside important tertiary-care capabilities. Canada and the United States have advanced interventional centers, with access shaped by regulatory review, reimbursement, and institutional protocols. China and India are expanding procedural capacity while balancing domestic production, affordability, and uneven distribution of expertise. Japan and South Korea combine sophisticated hospitals with demanding quality and regulatory expectations. France, Germany, Italy, and Spain operate within European clinical and regulatory frameworks, with adoption influenced by hospital budgets, evidence, and specialist networks. The United Kingdom places strong emphasis on clinical governance, health-system value, and centralized or coordinated purchasing. Russia's access environment is influenced by regulatory conditions, supply-chain resilience, and the availability of specialized infrastructure.

Action Priorities for Industry Leaders in Infusion Balloon Catheters

Industry leaders should prioritize clinically meaningful differentiation, including dependable deliverability, controlled infusion, visibility, inflation performance, and compatibility with routine workflows. Evidence programs should connect technical performance with patient-relevant outcomes, procedural efficiency, and safety, while addressing the requirements of regulators, hospitals, and payers. Regional strategies should be tailored to local training needs, procurement systems, service capacity, and supply-chain conditions rather than assuming a uniform global pathway. Organizations should also strengthen post-market surveillance, cybersecurity practices for connected systems, clinician education, and partnerships that improve appropriate use without overstating capabilities.

Research Methodology: Evidence-Led Executive Assessment

This executive summary uses a structured assessment of the infusion balloon catheter category, focusing on clinical applications, product functionality, care-delivery trends, regulatory considerations, technology integration, and geographic health-system conditions. Regional, group, and country observations are framed as qualitative comparisons of infrastructure, access, policy, procurement, and specialist capacity. Artificial-intelligence commentary addresses relevant enabling technologies and implementation requirements, not unsupported claims of device-specific clinical performance. Conclusions are limited to evidence-supported strategic themes and exclude market estimates, market sizing, market shares, forecasts, and company-specific analysis.

Conclusion: Disciplined Evidence and Local Execution Will Guide Progress

Infusion balloon catheters remain relevant where clinicians need controlled intraprocedural delivery alongside balloon-based treatment. Their future development will depend on reliable device performance, clinically credible evidence, integration with imaging and digital workflows, and practical support for physicians and hospitals. Success across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific will require locally informed regulatory, reimbursement, training, and supply strategies. Leaders that combine patient-centered innovation with rigorous validation and responsible implementation will be best positioned to support safe and sustainable clinical adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infusion Balloon Catheter Market, by Product Type

• 7.1. Introduction
• 7.2. Drug Coated Balloon
• 7.3. Standard Balloon Catheter

8. Infusion Balloon Catheter Market, by Exchange Mechanism

• 8.1. Introduction
• 8.2. Over The Wire Catheter
• 8.3. Rapid Exchange Catheter

9. Infusion Balloon Catheter Market, by Balloon Material

• 9.1. Introduction
• 9.2. Nylon
• 9.3. Polyethylene Terephthalate
• 9.4. Polyurethane

10. Infusion Balloon Catheter Market, by Balloon Diameter

• 10.1. Introduction
• 10.2. Large (>5 mm)
• 10.3. Medium (2-5 mm)
• 10.4. Small (<2 mm)

11. Infusion Balloon Catheter Market, by Inflation Medium

• 11.1. Introduction
• 11.2. Contrast Agent
• 11.3. Saline Solution

12. Infusion Balloon Catheter Market, by Application

• 12.1. Introduction
• 12.2. Coronary Artery Intervention
• 12.3. Neurological Intervention
• 12.4. Peripheral Vascular Intervention

13. Infusion Balloon Catheter Market, by End User

• 13.1. Introduction
• 13.2. Ambulatory Surgical Centers
• 13.3. Cardiac Catheterization Laboratories
• 13.4. Hospitals

14. Infusion Balloon Catheter Market, by Region

• 14.1. Introduction
• 14.2. Asia-Pacific
• 14.3. North America
• 14.4. Latin America
• 14.5. Europe
• 14.6. Middle East
• 14.7. Africa

15. Infusion Balloon Catheter Market, by Group

• 15.1. Introduction
• 15.2. ASEAN
• 15.3. GCC
• 15.4. European Union
• 15.5. BRICS
• 15.6. G7
• 15.7. NATO

16. Infusion Balloon Catheter Market, by Country

• 16.1. Introduction
• 16.2. United States
• 16.3. Canada
• 16.4. Mexico
• 16.5. Brazil
• 16.6. United Kingdom
• 16.7. Germany
• 16.8. France
• 16.9. Russia
• 16.10. Italy
• 16.11. Spain
• 16.12. China
• 16.13. India
• 16.14. Japan
• 16.15. Australia
• 16.16. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. Market Concentration Analysis, 2025
  • 17.2.1. Concentration Ratio (CR)
  • 17.2.2. Herfindahl Hirschman Index (HHI)
• 17.3. Recent Developments & Impact Analysis, 2025
• 17.4. Product Portfolio Analysis, 2025
• 17.5. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. AngioDynamics, Inc.
• 18.3. B. Braun Melsungen AG
• 18.4. Becton, Dickinson and Company
• 18.5. BIOTRONIK SE & Co. KG
• 18.6. Boston Scientific Corporation
• 18.7. Cardinal Health, Inc.
• 18.8. Cook Medical Incorporated
• 18.9. Johnson & Johnson
• 18.10. Koninklijke Philips N.V.
• 18.11. Lepu Medical Technology (Beijing) Co., Ltd.
• 18.12. MedAlliance SA
• 18.13. Medtronic PLC
• 18.14. Merit Medical Systems, Inc.
• 18.15. MicroPort Scientific Corporation
• 18.16. Natec Medical, Ltd.
• 18.17. Smiths Medical, Inc.
• 18.18. Surmodics, Inc.
• 18.19. Teleflex Incorporated
• 18.20. Terumo Corporation

19. Key Experts